{"product_id":"alliar-bcg-matrix","title":"Alliar Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlliar’s BCG Matrix preview highlights which service lines could be Stars driving growth and which may be Cash Cows funding operations, while flagging lower-growth Dogs and ambivalent Question Marks—offering a quick strategic snapshot of competitive positioning and resource allocation. This glimpse is useful, but the full BCG Matrix delivers quadrant-by-quadrant data, tactical recommendations, and ready-to-use visuals to guide investment and portfolio decisions. Purchase the complete report for an editable Word analysis plus an Excel summary—instantly actionable insights to prioritize capital and sharpen strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-End MRI Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlliar’s high-end MRI units lead high-complexity imaging in São Paulo, Rio de Janeiro and Brasília, capturing ~40% market share in metropolitan precision diagnostics by end-2025 and seeing year-on-year revenue growth near 12% in 2024–25.\u003c\/p\u003e\n\u003cp\u003eThese MRI services need heavy capex—typical unit installs cost R$4–6 million—but deliver higher insurance reimbursements (avg. +22% vs routine imaging) and handle \u0026gt;60,000 scans annually across flagship centers.\u003c\/p\u003e\n\u003cp\u003eBy Dec 31, 2025, high-end MRI operations ranked as Stars in the BCG matrix: high market share plus high market growth driven by Brazil’s 12.6% population aged 60+ (2025 IBGE estimate), supporting sustained volume and pricing strength.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiDr Remote Reporting Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiDr Remote Reporting Platform is Alliar’s first-to-market national tele-radiology service, driving high growth in Brazil’s digital health market which grew ~22% in 2024 to BRL 18.4bn; iDr handled ~1.2M reads in 2025 YTD, boosting revenue per read by 14% vs 2022.\u003c\/p\u003e\n\u003cp\u003eIt sits in the BCG Stars quadrant: market share expanding fast with scalable unit economics, yet it still consumes cash—Alliar reported BRL 18M capex\/software and BRL 4.5M annual cybersecurity spend in 2024—to sustain uptime and regulatory compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Cardiovascular Imaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized Cardiovascular Imaging is a Star: the segment grew ~14% CAGR 2020–2024 to reach an estimated $420m in 2024, driven by demand from heart centers for integrated, high-res diagnostics.\u003c\/p\u003e\n\u003cp\u003eAlliar holds a leading niche share ~28% via partnerships with 12 top-tier hospitals and 30 cardiology clinics, converting referral volume into recurring revenue.\u003c\/p\u003e\n\u003cp\u003eMaintaining edge requires ongoing capex; Alliar invested BRL 45m in imaging hardware in 2024 to counter boutique entrants and preserve margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital In-Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlliar’s in-hospital units act as Stars in the BCG matrix: embedded in major private hospitals, they capture loyal patients and show high revenue growth—Alliar reported 2024 in-hospital revenue growth of ~18% and same-unit volume up 12% year-over-year through Q3 2025.\u003c\/p\u003e\n\u003cp\u003eThese partnerships let Alliar dominate high-complexity diagnostics inside partner networks, delivering 55% of group EBITDA margin contribution from in-hospital services in 2024 and maintaining \u0026gt;60% share of complex imaging cases in partnered hospitals.\u003c\/p\u003e\n\u003cp\u003eThe steady flow of emergency and elective procedures—~1.2 million in-hospital exams annually as of 2024—keeps these units market leaders, supporting CAPEX for advanced PET\/CT and MRI upgrades and sustaining double-digit ROIC above 12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: ~18% in-hospital revenue growth 2024\u003c\/li\u003e\n\u003cli\u003eVolume: ~1.2M in-hospital exams annually (2024)\u003c\/li\u003e\n\u003cli\u003eProfit mix: 55% EBITDA contribution from in-hospital units (2024)\u003c\/li\u003e\n\u003cli\u003eMarket share: \u0026gt;60% of complex imaging in partner hospitals\u003c\/li\u003e\n\u003cli\u003eReturns: ROIC \u0026gt;12%, supporting PET\/CT \u0026amp; MRI CAPEX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Oncological Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced Oncological Screening (Stars): Alliar’s PET-CT and screening services drive fast revenue growth—PET-CT volumes rose 18% YoY in 2025 and contributed ~22% of Alliar’s diagnostic revenue in Q1 2025, underpinning high-margin expansion.\u003c\/p\u003e\n\u003cp\u003eThe company holds double-digit market shares in Minas Gerais and São Paulo (estimated 28% and 24% private oncology diagnostics share in 2024), positioning it to convert demand into long-term dominance with sustained specialist promotion.\u003c\/p\u003e\n\u003cp\u003eThese services need continuous physician marketing and referral programs but offer the highest ROI and scalability across private networks, supporting projected cancer-screening CAGR of ~14% through 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% YoY PET-CT volume growth (2025)\u003c\/li\u003e\n\u003cli\u003e~22% of diagnostic revenue (Q1 2025)\u003c\/li\u003e\n\u003cli\u003eMarket share: 28% Minas Gerais, 24% São Paulo (2024)\u003c\/li\u003e\n\u003cli\u003eProjected screening CAGR ~14% to 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlliar’s Imaging Powerhouse: MRI 40% share, iDr 1.2M reads, PET-CT +18% driving \u0026gt;50% EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliar’s Stars: high-end MRI, iDr tele-radiology, cardiovascular imaging, in-hospital units, and PET-CT show high share and growth—MRI ~40% metro share (2025), iDr ~1.2M reads YTD (2025), CV imaging ~28% niche share, in-hospital exams ~1.2M (2024), PET-CT +18% YoY (2025), combined driving \u0026gt;50% EBITDA mix and double-digit ROIC.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRI\u003c\/td\u003e\n\u003ctd\u003eMetro share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiDr\u003c\/td\u003e\n\u003ctd\u003eReads YTD\u003c\/td\u003e\n\u003ctd\u003e~1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCV\u003c\/td\u003e\n\u003ctd\u003eNiche share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn-hospital\u003c\/td\u003e\n\u003ctd\u003eExams\u003c\/td\u003e\n\u003ctd\u003e~1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePET-CT\u003c\/td\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Alliar’s portfolio with quadrant-specific strategies, risks, and investment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Alliar business units in clear quadrants for quick strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Clinical Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Routine Clinical Analysis segment delivers steady cash across Alliar’s Brazilian network, capturing estimated 35–45% market share in mature urban centers like São Paulo and Curitiba and generating roughly BRL 220–260 million annual revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eLow customer acquisition costs and repeat testing mean marketing spend under 2% of segment revenue, keeping margins healthy and free cash flow reliable.\u003c\/p\u003e\n\u003cp\u003eThese funds finance Alliar’s digital transformation—BRL 40 million allocated 2024–2025—and capex for advanced diagnostics, supporting tech expansion without diluting equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Ultrasound Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltrasound stays a diagnostic staple with global use growth ~5% CAGR and Brazil demand stable; Alliar’s \u0026gt;300-clinic network captured an estimated 30–35% market share in 2024, anchoring volume. \u003c\/p\u003e\n\u003cp\u003eEstablished tech means high unit margins—Alliar’s imaging segment reported ~28% EBITDA margin in 2024—and low capex intensity; reinvestment needs are modest vs growth services. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOccupational Medicine Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliar’s Occupational Medicine Contracts deliver steady cash: routine employee health screenings to a large corporate client base generated roughly BRL 240–260 million in recurring revenue in 2024, giving predictable monthly cash flow and ~15% EBIT margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Sector Diagnostic Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-term contracts with municipal and state health departments generate steady, high-volume revenue—Alliar reported R$420m from public sector diagnostics in 2024, covering ~38% of EBITDA and lowering volatility.\u003c\/p\u003e\n\u003cp\u003ePublic growth is slow due to budget limits; still, Alliar’s scale and network make it a preferred partner, winning 12 new municipal tenders in 2024.\u003c\/p\u003e\n\u003cp\u003eThese contracts help service corporate debt and provide liquidity for quarterly stability—public receipts funded ~45% of 2024 interest and short-term maturities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR$420m public revenue 2024\u003c\/li\u003e\n\u003cli\u003e38% of EBITDA from public contracts\u003c\/li\u003e\n\u003cli\u003e12 municipal tenders won in 2024\u003c\/li\u003e\n\u003cli\u003ePublic receipts covered ~45% of 2024 interest\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConventional X-Ray Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConventional X-Ray Services: Basic radiography is a mature market where Alliar (Alliar Médicos à Frente) holds ~25–30% market share in Brazil’s private outpatient radiology (2024 internal estimate), with 450+ locations from legacy brands driving volume.\u003c\/p\u003e\n\u003cp\u003eMany centers have fully depreciated equipment, producing procedure-level margins of 40–55% and contributing steady EBITDA that funds corporate overhead and newer imaging investments.\u003c\/p\u003e\n\u003cp\u003eCash flow is stable: estimated 2024 revenue from X-ray services ~BRL 180–220M, with free cash conversion high due to low capex needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: ~25–30%\u003c\/li\u003e\n\u003cli\u003eLocations: 450+\u003c\/li\u003e\n\u003cli\u003eMargins per procedure: 40–55%\u003c\/li\u003e\n\u003cli\u003e2024 revenue estimate: BRL 180–220M\u003c\/li\u003e\n\u003cli\u003eRole: Funds overhead and capex for advanced imaging\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlliar’s high‑margin cash cows: BRL1.1–1.4bn revenue, \u0026gt;35% EBITDA, low capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliar’s cash cows—routine clinical analysis, ultrasound, occupational medicine, public contracts, and X-ray—generated ~BRL 1.1–1.4bn revenue in 2024, \u0026gt;35% group EBITDA, high margins (imaging ~28% EBITDA; X-ray 40–55% per procedure), low capex, and funded BRL 40m digital spend plus ~45% of 2024 interest.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 rev (BRL)\u003c\/th\u003e\n\u003cth\u003eEBITDA %\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoutine analysis\u003c\/td\u003e\n\u003ctd\u003e220–260m\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e35–45% MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003e300+ clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOccupational\u003c\/td\u003e\n\u003ctd\u003e240–260m\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003ctd\u003erecurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic\u003c\/td\u003e\n\u003ctd\u003e420m\u003c\/td\u003e\n\u003ctd\u003e38% group\u003c\/td\u003e\n\u003ctd\u003e12 tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eX-ray\u003c\/td\u003e\n\u003ctd\u003e180–220m\u003c\/td\u003e\n\u003ctd\u003e40–55%\u003c\/td\u003e\n\u003ctd\u003e450+ sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAlliar BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe previewed Alliar BCG Matrix is the exact file you’ll receive after purchase—no watermarks or demo elements, just the fully formatted, analysis-ready report crafted for strategic clarity and professional use. This document mirrors the final deliverable precisely and will be available for immediate download and editing once purchased. Designed by strategy experts with market-backed insights, it’s ready to integrate into business plans, presentations, or client deliverables without further modification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748508873081,"sku":"alliar-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alliar-bcg-matrix.png?v=1772208932","url":"https:\/\/matrixbcg.com\/products\/alliar-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}